So far, TCRm antibody-based therapeutics targeting WT-1 and AFP have been advanced to clinical trial phases, while many additional TCRm antibodies failed to advance further [4]
So far, TCRm antibody-based therapeutics targeting WT-1 and AFP haveRead More